Akebia Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Yahoo! Finance
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $12.2 million in its fourth quarter. The Cambridge, Massachusetts-based company said it had a loss of 5 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 3 cents per share. The kidney disease treatment developer posted revenue of $57.6 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $47.2 million. For the year, the company reported that its loss narrowed to $5.3 million, or 2 cents per share. Revenue was reported as $236.2 million. The company's shares closed at $1.22. A year ago, they were trading at $1.82. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AKBA at https://www.zacks.com/ap/AKBA
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090GlobeNewswire
- Akebia Therapeutics (AKBA) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.MarketBeat
- Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation SymposiumGlobeNewswire
- How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates [Yahoo! Finance]Yahoo! Finance
AKBA
Earnings
- 2/26/26 - Miss
AKBA
Sec Filings
- 4/15/26 - Form PRE
- 4/3/26 - Form 4
- 4/3/26 - Form 3
- AKBA's page on the SEC website